Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of dexamethasone (a corticosteroid) and procarbazine (an antineoplastic agent) used in various chemotherapy regimens for treating certain types of cancers, particularly Hodgkin's lymphoma and brain tumors. Dexamethasone helps reduce inflammation and immune system activity, and is often included to enhance the effectiveness of other drugs and manage side effects like nausea and vomiting[3][5]. Procarbazine is primarily used in combination with other chemotherapeutic drugs for treating Hodgkin's disease and gliomas[1][2], working by damaging cancer cell DNA[9]. This combination is found in regimens like PCV (procarbazine, lomustine, and vincristine) for brain tumors, where dexamethasone is used as an antiemetic[4], and certain lymphoma treatment protocols including a regimen of "methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone" for refractory lymphoma[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + procarbazine.